<DOC>
	<DOCNO>NCT00001049</DOCNO>
	<brief_summary>To determine pharmacokinetics , safety , efficacy didanosine ( ddI ) alone combination zidovudine ( AZT ) HIV-infected infant . PER AMENDMENT 4/8/97 : Part A study objective complete . Part B objectives : To assess safety , toxicity , tolerability compare anti-HIV activity , measure change log10 RNA , two study arm . Early treatment HIV-infected infant antiretroviral agent may prevent early rapid decline CD4 count immunologic function . Combination therapy may prefer monotherapy , since resistance single agent develop rapidly . Currently , little information ddI monotherapy young infant le 90 day information use combination therapy population .</brief_summary>
	<brief_title>A Study Didanosine Use Alone Combination With Zidovudine Infants Exposed Infected With HIV</brief_title>
	<detailed_description>Early treatment HIV-infected infant antiretroviral agent may prevent early rapid decline CD4 count immunologic function . Combination therapy may prefer monotherapy , since resistance single agent develop rapidly . Currently , little information ddI monotherapy young infant le 90 day information use combination therapy population . In Part A , cohort patient young 28 day ( less 120 day ; amend 6/20/95 ) age receive open-label ddI monotherapy 1 week initiation AZT/ddI combination therapy . After pharmacokinetic data obtain , additional cohort patient receive ddI high dose . An age-adjusted dose ddI determine use Part B . ( NOTE : As 2/13/95 , Part A complete accrued infant 29 120 day age . ) Part B patient less 90 day age ( le 180 day age ; amend 6/20/95 ) randomize , double-blind basis , receive ddI AZT/ddI . All patient continue treatment 12 month last patient Part B enrol . PER AMENDMENT 4/8/97 : Part A protocol close accrual objective meet . Part B study remain open patient accrual 6/2/97 . Part B design 2-arm , randomize , double-blind study ass safety , toxicity tolerability well anti-HIV activity ddI AZT/ddI .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Recommended : PCP prophylaxis . Allowed : Acetaminophen continual basis . NOTE : Drugs metabolize hepatic glucuronidation associate occurrence pancreatitis allow used caution . Patients must least one follow : Documented HIV infection . Been bear HIVinfected woman receive AZT . PER AMENDMENT 4/8/97 : Number 2 longer required closure Part A study . Patients must sign , inform consent parent legal guardian . PER 6/20/95 AMENDMENT , patient Part A must less 28 day age Part B must less 90 day age . PER 7/7/94 AMENDMENT , patient Part A less 120 day age Part B le 180 day age . NOTE : All patient must 34 week gestation birth . Prior Medication : Allowed : Prior vaccine therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Pancreatitis . Clinically unstable condition . Current participation vaccine trial , Part A , perinatal trial indeterminate infection status . Concurrent Medication : Excluded : Vaccine therapy . Patients follow prior condition exclude : Pancreatitis time since birth . Prior Medication : Excluded Part B patient : More 90 day prior antiretroviral immunomodulator therapy , exclusive therapy receive utero .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Months</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>